FRM
INBX

Fox Run Management’s Inhibrx, Inc. Common Stock INBX Stock Holding History

Fox Run Management’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-12,621
Closed -$232K – 1089
2023
Q3 		$232K Buy
+12,621
New +$264K 0.07% 521

Other funds holding INBX

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fox Run Management's INBX Position: Q4 2023 in Review

Fox Run Management sold out of Inhibrx, Inc. Common Stock (INBX) in Q4 2023, closing a stake of 12,621 shares — an estimated $232K sold.

Fox Run Management first reported a position in INBX in Q3 2023 and held it in 1 quarter. The position peaked at $232K in Q3 2023. 127 funds tracked by Wall St. Rank hold INBX as of Q4 2023.

  • Fox Run Management reported no remaining Inhibrx, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Fox Run Management sold 12,621 Inhibrx, Inc. Common Stock shares in Q4 2023, an estimated $232K.
  • Fox Run Management first reported a position in Inhibrx, Inc. Common Stock in Q3 2023 and held it in 1 quarter.
  • Fox Run Management's Inhibrx, Inc. Common Stock position peaked at $232K in Q3 2023.
  • 127 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q4 2023.

Based on Fox Run Management's 13F filing for Q4 2023, filed 13 Feb 2024.